9852 Federal Register / Vol. 60, No. 35 / Wednesday, February 22, 1995 / Notices

television providers in Columbus. TCI

and TeleCable are the two largest cable

television providers in the Columbus

area in terms of the number of

subscribers and the number of homes

passed.

the agreement containing consent

order would, if finally issued by the

Commission, settle charges alleged in

the Commission’s complaint that TCI’s

acquisition of TeleCable would

substantially lessen competition in the

distribution of multichannel video

programming by cable television in the

Columbus, Georgia, area, in violation of

Section 7 of the Clayton Act. The nature

of such competition to be preserved is

actual competition to serve existing

homes, hotels, and apartment

complexes. The order will also preserve

competition for providing cable service

to new housing developments and other

presently cabled portions of the

Columbus area. The Commission’s

complaint further alleges that TCI’s

merger agreement with TeleCable

violates Section 5 of the Federal Trade

Commission Act.

The order accepted for public

comment would require TCI to divest a

cable television system in the

Columbus, Georgia, area. If TCI fails to

divest a system within one year, the

order allows the Commission to

appointment a trustee to sell a cable

system. A hold separate agreement

executed in conjunction with the

consent agreement requires TCI, until

completion of the divestiture (or as

otherwise specified), to maintain

TeleCable’s Columbus cable system

separate from TCI’s other operations.

For ten (10) years from the date the

order becomes final, the order would

also prohibit TCI, without obtaining

prior Commission approval, from

acquiring any cable television system in

the Columbus, Georgia, area.

The purpose of this analysis is to

invite public comment concerning the

consent order. This analysis is not

intended to constitute an official

interpretation of the agreement and

order or to modify their terms in any

way.

By direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 95–4280 Filed 2–21–95; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Meeting

Pursuant to Pub. L. 92–463, notice is

hereby given of the meeting of the

Acrylonitrile Study Advisory Panel,

National Cancer Institute, National

Institutes of Health, on Friday March 24,

1995. The meeting will be held in

Conference Room H, Executive Plaza

North, 6130 Executive Boulevard,

Rockville, Maryland 20892.

This meeting will be open to the

public from 10 am to 5 pm for

discussion and review of study progress.

Attendance by the public will be limited

to space available.

Ms. Carole A. Frank, Committee

Management Officer, National Cancer

Institute, Executive Plaza North, Room

630, National Institutes of Health,

Bethesda, Maryland 20892 (301/496–

5708) will provide summaries of the

meeting and rosters of committee

members, upon request.

Dr. Aaron Blair, Executive Secretary,

Division of Cancer Etiology, National

Cancer Institute, National Institutes of

Health, Executive Plaza North, Room

418, 6130 Executive Boulevard,

Rockville, Maryland 20892 (301/496–

9093) will furnish substantive program

information.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other special

accommodations, should contact Dr.

Aaron Blair, (301) 496–9093, in advance

of the meeting.

Dated: February 15, 1995.

Susan K. Feldman,

Committee Management Officer, National

Institutes of Health.

[FR Doc. 95–4244 Filed 2–21–95; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Health

National Cancer Institute; Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the National Cancer

Institute (NCI) advisory committee

meetings.

These meetings will be open to the

public as indicated below with

attendance limited to space available.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

notify the contact person in advance of

the meeting.

Ms. Carole Frank, NCI Committee

Management Officer, National Institutes

of Health, Executive Plaza North, Room

630E, 6130 Executive Boulevard MSC

7405, Bethesda, Maryland 20892–7405,

(301) 496–5708, will provide summaries

of the meetings and rosters of committee

members upon request. Substantive

program information may be obtained

from the contacts listed below.

Committee Name: Developmental

Therapeutics Contracts Review

Committee.

Contact Person: Dr. C. Michael Kerwin,

Scientific Review Administrator,

DEA, NCI, NIH, Executive Plaza

North, Room 601A, 6130 Executive

Boulevard, Rockville, MD 20852–

7405, Telephone: (301) 496–7421

Date of Meeting: March 3, 1995

Place of Meeting: Executive Plaza North,

Conference Room J, 6130 Executive

Boulevard, Rockville, MD 20852

Closed: 9 am to adjournment

Agenda: Review, discussion and

evaluation of individual contract

proposals.

Committee Name: Board of Scientific

Counselors, Division of Cancer

Biology, Diagnosis, and Centers

Contact person: Dr. Ihor J. Masnyk,

Executive Secretary, NCI, NIH,

Building 31A, Room 3A11, 9000

Rockville Pike, Bethesda, MD 20892–

2440, Telephone: (301) 496–3251

Date of Meeting: March 6, 1995

Place of Meeting: Building 31C—

Conference Room 10, National

Institutes of Health, 9000 Rockville

Pike, Rockville, MD 20892

Open: 8:30 am to adjournment

Agenda: Discussion and review of the

division budget and review of

concepts for grants and contracts.

These meetings will be closed, as

indicated, in accordance with

provisions set forth in secs. 552b(c)(4)

and 552b(c)(6), Title 5, U.S.C. Proposals

and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material

and personal information concerning

individuals associated with the

proposals, disclosure of which would

constitute a clearly unwarranted

invasion of personal privacy.

This notice is being published less

than fifteen days prior to the meeting

due to the urgent need to meet timing

limitations imposed by the review cycle.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower;

93.399, Cancer Control)
Federal Register / Vol. 60, No. 35 / Wednesday, February 22, 1995 / Notices 9853

* Applicants who wish to use express mail or

courier service should change the zip code to

20817–7710.

Dated: February 15, 1995.

Susan K. Feldman,

Committee Management Officer, National

Institutes of Health.

[FR Doc. 95–4242 Filed 2–21–95; 8:45 am]

BILLING CODE 4140–01–M

National Institutes of Health

National Institute of Mental Health;

Closed Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings of the National Institute of

Mental Health Initial Review Group:

Agenda/Purpose: To review and

evaluate grant applications

Committee Name: Child

Psychopathology and Treatment

Review Committee

Date: March 1–3, 1995

Time: 9 a.m.

Place: Wyndham Brystol Hotel, 2430

Pennsylvania Avenue NW.,

Washington, DC 20037

Contact Person: Bernice R. Cherry,

Grants Technical Assistant, Parklawn

Building, Room 9C–18, 5600 Fishers

Lane, Rockville, MD 20857,

Telephone: 301, 443–1367

Committee Name: Mental Health AIDS

and Immunology Review

Committee—1

Date: March 2–3, 1995

Time: 8:30 a.m.

Place: Hyatt Regency Bethesda, One

Bethesda Metro Center, Bethesda, MD

20814

Contact Person: Regina M. Thomas,

Grants Technical Assistant, Parklawn

Building, Room 9C–26, 5600 Fishers

Lane, Rockville, MD 20857,

Telephone: 301, 443–6470

Committee Name: Epidemiology and

Genetics Review Committee

Date: March 5–7, 1995

Time: 9 a.m.

Place: Embassy Suites at Chevy Chase,

4300 Military Road, NW.,

Washington, DC 20015

Contact Person: Bernice R. Cherry,

Grants Technical Assistant, Parklawn

Building, Room 9C–18, 5600 Fishers

Lane, Rockville, MD 20857,

Telephone: 301, 443–1367

Committee Name: Mental Health AIDS

and Immunology Review

Committee—2

Date: March 6–7, 1995

Time: 8:30 a.m.

Place: Hyatt Regency Bethesda, One

Bethesda Metro Center, Bethesda, MD

20814

Contact Person: Rehana A. Chowdhury,

Grants Technical Assistant, Parklawn

Building, Room 9C–26, 5600 Fishers

Lane, Rockville, MD 20857,

Telephone: 301, 443–6470

The meetings will be closed in

accordance with the provisions set forth

in sec. 552b(c)(4) and 552b(c)(6), Title 5,

U.S.C. Applications and/or proposals

and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material

and personal information concerning

individuals with the applications and/or

proposals, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

This notice is being published less

than fifteen days prior to the meeting

due to the urgent need to meet timing

limitations imposed by the intramural

research review cycle.

(Catalog of Federal Domestic Assistance

Program Numbers 93.126, Small Business

Innovation Research; 93.176, ADAMHA

Small Instrumentation Program Grants;

93.242, Mental Health Research Grants;

93.281, Mental Research Scientist

Development Award and Research Scientists

Development Award for Clinicians; 93.282,

Mental Health Research Service Awards for

Research Training; and 93.921, ADAMHA

Science Education Partnership Award.

Dated: February 15, 1995.

Susan K. Feldman,

Committee Management Officer, National

Institutes of Health.

[FR Doc. 95–4243 Filed 2–21–95; 8:45 am]

BILLING CODE 4140–01–M

Substance Abuse and Mental Health

Services Administration

Fiscal Year (FY) 1995 Notices of

Funding Availability

AGENCY: Substance Abuse and Mental

Health Services Administration

(SAMHSA), HHS.

ACTION: Correction notice.

SUMMARY: Public notice was given in the

Federal Register on February 10, 1995,

Volume 60, No. 28, pages 7980–7984, of

the funding opportunities for grants and

cooperative agreements from the Center

for Substance Abuse Prevention (CSAP)

during FY 1995. On page 7983, under

the Eligible Applicants section of 4.1.3

Community Prevention Coalitions

Demonstration Grant Program, a

statement was included that ‘‘the

applicant must be part of an existing

community partnership and must be

designated to act on behalf of the larger

coalition of multiple partnerships

proposed in the grant application.’’

The requirement that the applicant

must be part of an existing partnership

has been deleted, and the revised

Eligible Applicants section now states

that ‘‘the applicant must be designated

to act on behalf of the larger evolving

coalition of multiple partnerships

proposed in the grant application.’’

Public notice was also given in the

Federal Register on: January 4, 1995,

Volume 60, No. 2, pages 474–478;

January 30, 1995, Volume 60, No. 19,

pages 5688–5691; and February 10,

1995, Volume 60, No. 28, pages 7977–

7984; of the availability of funds from

the SAMHSA Centers—Center for

Mental Health Services, Center for

Substance Abuse Prevention, and Center

for Substance Abuse Treatment—for

grant and cooperative agreement

activities during FY 1995.

These notices specified that

competing grant and cooperative

agreement applications should be

submitted to the Division of Research

Grants, NIH, Westwood Building-Room

240, 5333 Westbard Avenue, Bethesda,

MD 20892.

The mailing address for the Division

of Research Grants, NIH, is being

changed. Effective April 21, 1995, all

competing SAMHSA applications must

be sent to: Division of Research Grants,

National Institutes of Health, 6701

Rockledge Drive MSC–7710, Bethesda,

MD 20892–7710.*

Dated: February 16, 1995.

Richard Kopanda,

Acting Executive Officer, SAMHSA.

[FR Doc. 95–4323 Filed 2–21–95; 8:45 am]

BILLING CODE 4162–20–P

Cooperative Agreement with the

Pennsylvania Department of Health

AGENCY: Center For Substance Abuse

Treatment, Substance Abuse and Mental

Health Services Administration

(SAMHSA), HHS.

ACTION: Notice of a planned single

source, cooperative agreement award to

support further development and

continuation of a model comprehensive

substance abuse treatment

demonstration program for the City of

Philadelphia.

SUMMARY: The Center for Substance

Abuse Treatment (CSAT), SAMHSA, is

publishing this notice to provide

information to the public regarding a

planned single source competing

continuation award to the Pennsylvania

Department of Health for the further

development and operation of a model

substance abuse treatment

demonstration program. The current

‘‘Target Cities’’ project period will be